Torsten earned his MD and PhD from Copenhagen University. After a postdoctoral fellowship at the Molecular Psychiatry Lab at Yale Medical School and clinical training in psychiatry, he continued his career in clinical drug development. He has been responsible for development programs in multiple indications, spanning all phases of drug development. He has international leadership experience in biotech and the pharmaceutical industry, both from public and privately held companies, most recently from Syndesi Therapeutics, acquired by Abbvie in 2022.